← Back to Search

Financial Incentives for Type 2 Diabetes (LIFT-FINANCE Trial)

N/A

Waitlist Available

Led By Rebekah J Walker, PhD

Research Sponsored by Medical College of Wisconsin

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Clinical diagnosis of type 2 diabetes

Age 21 years or older

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6-months post randomization

Awards & highlights

LIFT-FINANCE Trial Summary

This trial will test if financial incentives can help improve HbA1c, blood pressure, and quality of life in food insecure adults with type 2 diabetes.

Who is the study for?

This trial is for adults over 21 with type 2 diabetes, an HbA1c of 9 or higher, and who struggle to afford food. They must speak English and not have dementia, drug/alcohol dependency, severe mental disorders, be in another diabetes study, or have less than a six-month life expectancy.Check my eligibility

What is being tested?

The study tests if financial rewards can help people with type 2 diabetes eat better and manage their blood sugar levels. Participants will receive one of three types of cash incentives plus monthly educational materials about managing diabetes through diet.See study design

What are the potential side effects?

There are no direct medical side effects from participating in this trial as it involves financial incentives and education rather than medication. However, changes in diet based on the provided information could indirectly affect health.

LIFT-FINANCE Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with type 2 diabetes.

Select...

I am 21 years old or older.

LIFT-FINANCE Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6-months post randomization

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6-months post randomization

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6-months post randomization for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Glycemic control (HbA1c)

Secondary outcome measures

Blood pressure (both systolic and diastolic)

Quality of life as measured by the Short Form Health Survey (SF-12)

LIFT-FINANCE Trial Design

3Treatment groups

Experimental Treatment

Group I: Monthly Unconditional Plus Healthy Food Purchasing Plus Glycemic Control Financial IncentiveExperimental Treatment4 Interventions

Individuals assigned to this group will receive diabetes education, a monthly incentive to supplement income and enhance ability to purchase healthy food options, an additional weekly incentive if receipt for purchase of healthy food items from a grocery store is provided, and an incentive at the end of the study based on absolute drop in HbA1c.

Group II: Monthly Unconditional Plus Healthy Food Purchasing Financial IncentiveExperimental Treatment3 Interventions

Individuals assigned to this group will receive diabetes education, a monthly incentive to supplement income and enhance ability to purchase healthy food options, and an additional weekly incentive if receipt for purchase of healthy food items from a grocery store is provided.

Group III: Monthly Unconditional Financial IncentiveExperimental Treatment2 Interventions

Individuals assigned to this group will receive diabetes education and a monthly incentive to supplement income and enhance ability to purchase healthy food options.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Diabetes Education

2019

Completed Phase 3

~2550

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Medical College of WisconsinLead Sponsor

609 Previous Clinical Trials

1,162,451 Total Patients Enrolled

Rebekah J Walker, PhDPrincipal InvestigatorMedical College of Wisconsin

1 Previous Clinical Trials

300 Total Patients Enrolled

Media Library

Glycemic Control Financial Incentive Clinical Trial Eligibility Overview. Trial Name: NCT05352022 — N/A

Type 2 Diabetes Research Study Groups: Monthly Unconditional Plus Healthy Food Purchasing Plus Glycemic Control Financial Incentive, Monthly Unconditional Plus Healthy Food Purchasing Financial Incentive, Monthly Unconditional Financial Incentive

Type 2 Diabetes Clinical Trial 2023: Glycemic Control Financial Incentive Highlights & Side Effects. Trial Name: NCT05352022 — N/A

Glycemic Control Financial Incentive 2023 Treatment Timeline for Medical Study. Trial Name: NCT05352022 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment for this clinical trial currently available?

"Affirmative, the statistics available on clinicaltrials.gov demonstrate that this examination is presently enrolling participants. The trial was initially posted on May 1st 2022 and has been updated most recently August 23rd 2022. This study requires 150 subjects to be recruited from a single research centre."

Answered by AI

What is the current limit of participants for this experimentation?

"Affirmative. According to clinicaltrials.gov, this trial which originated on May 1st 2022 is still searching for subjects. There are 150 potential candidates needed at a single medical centre."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Lowering Food Insecurity and Improving Diabetes With Financial Incentives

Rebekah Walker 2022. "Lowering Food Insecurity and Improving Diabetes With Financial Incentives". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05352022.

All > Diabetes Type 2